1 / 8

Perceptions of AstraZeneca in Cardiovascular Medicine

Perceptions of AstraZeneca in Cardiovascular Medicine. Research Sample. Cardiologist Practice Setting. Cardiologist Hospital Type. One hour In-Depth Interviews (IDIs) with 60 treaters of CV disease across France, Italy and the UK. Satisfaction with Current Treatments.

cullen-head
Download Presentation

Perceptions of AstraZeneca in Cardiovascular Medicine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Perceptions of AstraZeneca in Cardiovascular Medicine

  2. Research Sample Cardiologist Practice Setting Cardiologist Hospital Type One hour In-Depth Interviews (IDIs) with 60 treaters of CV disease across France, Italy and the UK

  3. Satisfaction with Current Treatments Atherosclerosis ACS BP Lipids Dissatisfied Satisfied • To Slow Atherosclerosis • Data shows this can be achieved with high dose statins, however these doses are not often used • Some scepticism about real world practicality • To Prevent Events in ACS • Can reduce the risk, but still the biggest risk factor for having a heart attack is already having had one • To Control BP • Can get most people to goal but often need combination treatment • Satisfaction would be higher if you could achieve goal with monotherapy • To Control Blood Lipids • Generally satisfied, good range of drugs available though improved efficacy would be desirable especially in primary prevention “There’s not a magic drug. We get most people controlled on 1,2 or 3 agents with quite a lot of dose adjustment“ UK, Card "Controlling atherosclerosis is something we'd really like to do, but at the present it's just utopic“ Ita, Card “Drugs are okay, but events still occur - for several different reasons it’s difficult to control“ Fra, PCP "I'm satisfied with lipid control because current agents are complete in terms of effects” Ita, Card Satisfaction with ability to control blood lipids and blood pressure is relatively high Base: All respondents (n=60) rated their satisfaction with treatments on a 0 - 100 scale with 100 being fully satisfied

  4. Perceived Range of CV Products 6 5 5 3 2 1 AZ, Pfizer and Sanofi were ranked highest for the range of their CV products Base: All respondents (n=60) Respondents ranked top 5 companies, from 1-5, from list of 20

  5. Perceived Commitment to and Treatments for CV Disease “AstraZeneca has a long term commitment to CV – they’ve always been present with various molecules” Fra, Card 6 5 5 3 2 • AZ was ranked highest because of their diverse products, their research activity and support of CME • Sanofi was second because of their products and the level of support (education, information, materials) they provide • Pfizer was third because of their products and their support of CME AZ was ranked highest for its perceived commitment to physicians in treating CV disease, followed by Sanofi, Pfizer and Novartis Base: All respondents (n=60) Respondents ranked top 5 companies, from 1-5, from list of 20

  6. PCPs – Spontaneous Mentions of Franchises (Across all Therapy Areas) • Many respondents stated that many companies now offer a range of products and are no longer differentiated • Rationale for mentioning an individual company was typically current provision of good product(s) rather than service provision etc. • AZ mentions centred strongly around lipid lowering with no mentions of other CV products Diabetology Lipid lowering Hypertension/CV Lipid lowering & Hypertension Respiratory Hypertension Gastroenterology AZ was mentioned by PCPs most frequently for (lipid lowering> respiratory> gastroenterology franchises) Osteoporosis Respiratory Lipid lowering

  7. Cardiologists – Spontaneous Mentions of CV Franchises • Relatively small number of companies were seen as having a franchise in cardiology • Current provision of good product(s) was the main reason for a company to be suggested • Sanofi was most mentioned and was strongly associated with OAP • AZ mentions were again centred strongly around lipid lowering with one mention of OAPs Lipid lowering OAP Hypertension/OAP “The only thing that matters to me is the drug; they all have a beta-blocker, an ACE inhibitor and a Ca antagonist, no one is better than the others" Ita, PCP Lipid lowering & Hypertension Hypertension Hypertension/ Angina Sanofi was most commonly mentioned as having a CV franchise, Pfizer and AZ were seen as leading in lipid lowering Lipid lowering

  8. CV Franchise Preference Least willing to lose 1.0 2.0 3.0 4.0 5.0 6.0 Most willing to lose AZ was the CV franchise respondents said they would be least willing to lose because of products, support and innovation 1478101 10/11 Base: All respondents (n=60) Respondents ranked franchises from 6 (would be most willing to lose) to 1 (would be least…)

More Related